Inmune Bio (INMB) Return on Capital Employed (2019 - 2026)
Inmune Bio (INMB) posted Return on Capital Employed of 182.69% for Q1 2026, up 5.78% sequentially from 193.89% in Q4 2025, and down 4767.0% YoY from 3.91% in Q1 2025.
Inmune Bio (INMB) Return on Capital Employed (2019 - 2026) Analysis & Trends
Inmune Bio has reported Return on Capital Employed for 8 years, with the latest figure at 182.69% in Q1 2026.
- Quarterly Return on Capital Employed fell 4767.0% year-over-year to 182.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 182.69% (down 4767.0% YoY) and the FY2025 annual result came in at 172.05%, down 6821.0% from the prior year.
- Return on Capital Employed improved to 182.69% in Q1 2026 per INMB's latest filing, from 193.89% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 33.09% in Q1 2022 and troughed at 193.89% in Q4 2025.
- A 5-year average of 85.64% and a median of 71.87% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed sank 309 bps in 2022, then sank 8443 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 36.1% in 2022, then slumped by 99 bps to 71.87% in 2023, then tumbled by 52 bps to 109.46% in 2024, then plunged by 77 bps to 193.89% in 2025, then increased by 6 bps to 182.69% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 182.69%, 193.89%, and 135.01% for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -98.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -98.79% |
| Mar 31, 2026 | -182.69% |
| Dec 31, 2025 | -193.89% |
| Mar 31, 2025 | -135.01% |
| Dec 31, 2024 | -109.46% |
| Sep 30, 2024 | -107.10% |
| Jun 30, 2024 | -109.24% |
| Mar 31, 2024 | -99.62% |
| Dec 31, 2023 | -71.87% |
| Sep 30, 2023 | -52.08% |
| Jun 30, 2023 | -44.08% |
| Mar 31, 2023 | -38.31% |
| Dec 31, 2022 | -36.10% |
| Sep 30, 2022 | -37.18% |
| Jun 30, 2022 | -34.82% |
| Mar 31, 2022 | -33.09% |
| Dec 31, 2021 | -29.31% |
| Sep 30, 2021 | -29.39% |
| Jun 30, 2021 | -31.73% |
| Mar 31, 2021 | -28.75% |